Analytical Data
-
基因名
HLA-A*02:01&B2M&HIV Gag(SLYNTVATL) Monomer
- Application
-
别名
HLA-A*0201 & B2M & HIV Gag (SLYNTVATL)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAA59606.1 (G25-I308)&P61769
-
表达区间
AAA59606.1 (G25-I308)&P61769 (I21-M119)&SLYNTVATL
-
分子量
40-43 kDa and 14 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*02:01-B2M-HIV Gag (SLYNTVATL) monomer recombinant protein is a significant focus in immunological research due to its potential applications in HIV vaccine development and cellular immunity studies. HLA-A*02:01 is one of the most common human leukocyte antigen (HLA) class I molecules, playing a critical role in presenting viral peptides, such as the renowned HIV Gag-derived epitope SLYNTVATL, to CD8+ T cells, which are vital for effective immune responses. The interaction between HLA-A*02:01 and the HIV Gag peptide is crucial for understanding how the immune system recognizes and reacts to HIV infections. By engineering a monomeric form of this complex, researchers aim to facilitate structural and functional studies that can elucidate the mechanisms of T cell recognition and activation. This approach not only aids in dissecting the intricate pathways of HIV pathogenesis but also paves the way for designing effective immunotherapies and vaccines that harness the body's immune response against HIV. Furthermore, employing such recombinant proteins can contribute to the development of tools for monitoring immune responses in vaccine trials, ultimately striving to achieve durable viral control in HIV-infected individuals.
